Suppr超能文献

胰岛素受体与G蛋白偶联受体的相互作用通过PI3K和PKD在胰腺癌细胞中刺激YAP

Insulin Receptor and GPCR Crosstalk Stimulates YAP via PI3K and PKD in Pancreatic Cancer Cells.

作者信息

Hao Fang, Xu Qinhong, Zhao Yinglan, Stevens Jan V, Young Steven H, Sinnett-Smith James, Rozengurt Enrique

机构信息

Tianjin Medical University, Tianjin, China.

Division of Digestive Disease, Department of Medicine, David Geffen School of Medicine, Los Angeles, California.

出版信息

Mol Cancer Res. 2017 Jul;15(7):929-941. doi: 10.1158/1541-7786.MCR-17-0023. Epub 2017 Mar 30.

Abstract

We examined the impact of crosstalk between the insulin receptor and G protein-coupled receptor (GPCR) signaling pathways on the regulation of Yes-associated protein (YAP) localization, phosphorylation, and transcriptional activity in the context of human pancreatic ductal adenocarcinoma (PDAC). Stimulation of PANC-1 or MiaPaCa-2 cells with insulin and neurotensin, a potent mitogenic combination of agonists for these cells, promoted striking YAP nuclear localization and decreased YAP phosphorylation at Ser and Ser Challenging PDAC cells with either insulin or neurotensin alone modestly induced the expression of YAP/TEAD-regulated genes, including connective tissue growth factor (), cysteine-rich angiogenic inducer 61 (), and , whereas the combination of neurotensin and insulin induced a marked increase in the level of expression of these genes. In addition, siRNA-mediated knockdown of YAP/TAZ prevented the increase in the expression of these genes. A small-molecule inhibitor (A66), selective for the p110α subunit of PI3K, abrogated the increase in phosphatidylinositol 3,4,5-trisphosphate production and the expression of , and induced by neurotensin and insulin. Furthermore, treatment of PDAC cells with protein kinase D (PKD) family inhibitors (CRT0066101 or kb NB 142-70) or with siRNAs targeting the PKD family prevented the increase of CTGF, CYR61, and CXCL5 mRNA levels in response to insulin and neurotensin stimulation. Thus, PI3K and PKD mediate YAP activation in response to insulin and neurotensin in pancreatic cancer cells. Inhibitors of PI3K or PKD disrupt crosstalk between insulin receptor and GPCR signaling systems by blocking YAP/TEAD-regulated gene expression in pancreatic cancer cells. .

摘要

我们研究了胰岛素受体与G蛋白偶联受体(GPCR)信号通路之间的串扰对人胰腺导管腺癌(PDAC)背景下Yes相关蛋白(YAP)定位、磷酸化及转录活性调控的影响。用胰岛素和神经降压素(这两种对这些细胞有强大促有丝分裂作用的激动剂组合)刺激PANC-1或MiaPaCa-2细胞,可显著促进YAP核定位,并降低YAP在Ser和Ser处的磷酸化。单独用胰岛素或神经降压素刺激PDAC细胞可适度诱导YAP/TEAD调控基因的表达,包括结缔组织生长因子()、富含半胱氨酸的血管生成诱导因子61()和,而神经降压素与胰岛素的组合则可显著增加这些基因的表达水平。此外,siRNA介导的YAP/TAZ敲低可阻止这些基因表达的增加。一种对PI3K的p110α亚基具有选择性的小分子抑制剂(A66),可消除神经降压素和胰岛素诱导的磷脂酰肌醇3,4,5-三磷酸生成增加以及、和的表达。此外,用蛋白激酶D(PKD)家族抑制剂(CRT0066101或kb NB 142-70)或靶向PKD家族的siRNAs处理PDAC细胞,可阻止胰岛素和神经降压素刺激后CTGF、CYR61和CXCL5 mRNA水平的增加。因此,PI3K和PKD介导胰腺癌细胞中胰岛素和神经降压素诱导的YAP激活。PI3K或PKD抑制剂通过阻断胰腺癌细胞中YAP/TEAD调控的基因表达来破坏胰岛素受体与GPCR信号系统之间的串扰。

相似文献

1
Insulin Receptor and GPCR Crosstalk Stimulates YAP via PI3K and PKD in Pancreatic Cancer Cells.
Mol Cancer Res. 2017 Jul;15(7):929-941. doi: 10.1158/1541-7786.MCR-17-0023. Epub 2017 Mar 30.
7
A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
Cancer Lett. 2017 Aug 28;402:61-70. doi: 10.1016/j.canlet.2017.05.015. Epub 2017 May 30.
8
A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo.
Mol Cancer Ther. 2010 May;9(5):1136-46. doi: 10.1158/1535-7163.MCT-09-1145. Epub 2010 May 4.

引用本文的文献

1
Effects of melatonin in polycystic ovary syndrome: is there Hippo pathway crosstalk?
J Ovarian Res. 2025 May 14;18(1):101. doi: 10.1186/s13048-025-01642-1.
2
Pancreatic endocrine and exocrine signaling and crosstalk in physiological and pathological status.
Signal Transduct Target Ther. 2025 Feb 14;10(1):39. doi: 10.1038/s41392-024-02098-3.
3
The Role of Pomegranate () in Cancer Prevention and Treatment: Modulating Signaling Pathways From Inflammation to Metastasis.
Food Sci Nutr. 2025 Jan 31;13(2):e4674. doi: 10.1002/fsn3.4674. eCollection 2025 Feb.
5
Stress and Obesity Signaling Converge on CREB Phosphorylation to Promote Pancreatic Cancer.
Mol Cancer Res. 2025 Mar 3;23(3):236-249. doi: 10.1158/1541-7786.MCR-24-0785.
7
Weight-centric prevention of cancer.
Obes Pillars. 2024 Mar 5;10:100106. doi: 10.1016/j.obpill.2024.100106. eCollection 2024 Jun.
10
YAP/TAZ: Molecular pathway and disease therapy.
MedComm (2020). 2023 Aug 9;4(4):e340. doi: 10.1002/mco2.340. eCollection 2023 Aug.

本文引用的文献

1
Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors.
Cancer Res. 2016 Dec 1;76(23):6851-6863. doi: 10.1158/0008-5472.CAN-16-1201. Epub 2016 Oct 14.
2
Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials.
Cancer Genet. 2016 Dec;209(12):567-581. doi: 10.1016/j.cancergen.2016.07.003. Epub 2016 Aug 2.
3
Body Fatness and Cancer--Viewpoint of the IARC Working Group.
N Engl J Med. 2016 Aug 25;375(8):794-8. doi: 10.1056/NEJMsr1606602.
5
YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK-STAT3 Signaling.
Gastroenterology. 2016 Sep;151(3):526-39. doi: 10.1053/j.gastro.2016.05.006. Epub 2016 May 20.
6
An obligatory role for neurotensin in high-fat-diet-induced obesity.
Nature. 2016 May 19;533(7603):411-5. doi: 10.1038/nature17662. Epub 2016 May 11.
7
Genetics and biology of pancreatic ductal adenocarcinoma.
Genes Dev. 2016 Feb 15;30(4):355-85. doi: 10.1101/gad.275776.115.
8
Cancer statistics, 2016.
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.
9
Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression.
Cancer Discov. 2016 Jan;6(1):80-95. doi: 10.1158/2159-8290.CD-15-0224. Epub 2015 Dec 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验